NTRK1 and gastrointestinal stromal tumor: Sunitinib (known also as SU11248 or Sutent), an orally active multi-targeted receptor tyrosine kinase inhibitor, was approved by the FDA in 2006 for the treatment of, i.a., advanced renal-cell carcinoma (RCC), pancreatic cancer (PC), chronic myeloid leukaemia and imatinib-resistant gastrointestinal stromal tumour (GIST) [31,32].